1. Academic Validation
  2. Discovery of Novel Selective Inhibitors of SMARCA2 ATPase Domain by Virtual Screening and Biological Evaluation

Discovery of Novel Selective Inhibitors of SMARCA2 ATPase Domain by Virtual Screening and Biological Evaluation

  • ACS Med Chem Lett. 2025 Sep 15;16(10):2032-2040. doi: 10.1021/acsmedchemlett.5c00459.
Jiawei Zhu 1 Xiaoxue Bai 1 Yucheng Xiong 1 Chenlong Xie 1 Yao Chen 2 Haopeng Sun 1
Affiliations

Affiliations

  • 1 School of Pharmacy, China Pharmaceutical University, Nanjing 211198, People's Republic of China.
  • 2 School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, People's Republic of China.
Abstract

The SWI/SNF chromatin remodeling complex regulates numerous cellular processes, and inactivating mutations in its subunit, SMARCA4, are closely associated with various malignancies. The inactivation of SMARCA4 has been found to have a synthetic lethal relationship with the inhibition of SMARCA2 ATPase, suggesting that targeted inhibition of SMARCA2 ATPase in SMARCA4-deficient environments presents a promising tumor treatment option. In this study, we identified binding pockets with selective modification potential through mixed-solvent molecular dynamics simulations. Additionally, several selective inhibitors of SMARCA2 ATPase were identified by virtual screening, and preliminary structural modifications were conducted. Among them, compounds 4 and 11 demonstrated inhibitory activity at micromolar level and exhibited selectivity. Overall, these findings validate the efficacy of our virtual screening approach and provide a promising novel scaffold for the development of highly selective SMARCA2 ATPase inhibitors.

Keywords

SMARCA2; SMARCA4; molecular dynamics; selective inhibitors; virtual screening.

Figures
Products